We also used the GEO data set GSE15222 ( Myers et al., 2007) to analyze the association of MAPT, RFX3, SLC1A1, and PPAPDC2 genes and case-control status. None of the other genes (GLIS3, GEMC1, IL1RAP, OSTN, FOXP4) were found in this data set. This data set includes genotype and expression data from 486 late onset Alzheimer’s disease cases and 279 neuropathologically clean individuals. Association of mRNA levels with case control status or the different SNPs was carried out using ANCOVA.

Stepwise regression analysis selleck compound was used to identify the potential covariates (postmortem interval, age at death, site, and gender) and significant covariates were included in the analysis. SNPs were tested using an additive model

with minor allele homozygotes coded as 0, heterozygotes coded as 1, and major allele homozygotes coded as 2. Data used in the preparation of this article were obtained from the ADNI database (www.loni.ucla.edu/ADNI). The ADNI was launched in 2003 by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, the Food and Drug Administration, private pharmaceutical companies, and nonprofit organizations, as a $60 million, 5 year public-private MG-132 order partnership. The Principal Investigator of this initiative is Michael W. Weiner, MD. ADNI is the result of efforts of many coinvestigators from a broad range of academic

institutions second and private corporations, and subjects have been recruited from over 50 sites across the US and Canada. The initial goal of ADNI was to recruit 800 adults, ages 55 to 90, to participate in the research—approximately 200 cognitively normal older individuals to be followed for 3 years, 400 people with MCI to be followed for 3 years, and 200 people with early AD to be followed for 2 years. For up-to-date information, see www.adni-info.org. This work was supported by grants from NIH (P30 NS069329-01, R01 AG035083, R01 AG16208, P50 AG05681, P01 AG03991, P01 AG026276, AG05136 and PO1 AG05131, U01AG032984, AG010124, and R01 AG042611), AstraZeneca, and the Barnes-Jewish Hospital Foundation. The authors thank the Clinical and Genetics Cores of the Knight ADRC at Washington University for clinical and cognitive assessments of the participants and for APOE genotypes and the Biomarker Core of the Adult Children Study at Washington University for the CSF collection and assays.